JP2021527062A5 - - Google Patents
Info
- Publication number
- JP2021527062A5 JP2021527062A5 JP2020567973A JP2020567973A JP2021527062A5 JP 2021527062 A5 JP2021527062 A5 JP 2021527062A5 JP 2020567973 A JP2020567973 A JP 2020567973A JP 2020567973 A JP2020567973 A JP 2020567973A JP 2021527062 A5 JP2021527062 A5 JP 2021527062A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- level
- complement factor
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024088364A JP2024114706A (ja) | 2018-06-07 | 2024-05-30 | ANCA関連血管炎に対するc5aアンタゴニストの投薬及び効果 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862682013P | 2018-06-07 | 2018-06-07 | |
| US62/682,013 | 2018-06-07 | ||
| PCT/US2019/035758 WO2019236820A1 (en) | 2018-06-07 | 2019-06-06 | Dosing and effect of c5a antagonist with anca-associated vasculitis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024088364A Division JP2024114706A (ja) | 2018-06-07 | 2024-05-30 | ANCA関連血管炎に対するc5aアンタゴニストの投薬及び効果 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021527062A JP2021527062A (ja) | 2021-10-11 |
| JP2021527062A5 true JP2021527062A5 (cg-RX-API-DMAC7.html) | 2022-06-13 |
Family
ID=68764799
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567973A Pending JP2021527062A (ja) | 2018-06-07 | 2019-06-06 | ANCA関連血管炎に対するc5aアンタゴニストの投薬及び効果 |
| JP2024088364A Pending JP2024114706A (ja) | 2018-06-07 | 2024-05-30 | ANCA関連血管炎に対するc5aアンタゴニストの投薬及び効果 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024088364A Pending JP2024114706A (ja) | 2018-06-07 | 2024-05-30 | ANCA関連血管炎に対するc5aアンタゴニストの投薬及び効果 |
Country Status (15)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021527062A (ja) | 2018-06-07 | 2021-10-11 | ケモセントリックス,インコーポレイティド | ANCA関連血管炎に対するc5aアンタゴニストの投薬及び効果 |
| CN113164403A (zh) | 2018-11-30 | 2021-07-23 | 凯莫森特里克斯股份有限公司 | 胶囊制剂 |
| AU2020380367B2 (en) | 2019-11-08 | 2026-06-04 | Chemocentryx, Inc. | Salt forms of a complement component C5a receptor |
| KR20220098754A (ko) | 2019-11-08 | 2022-07-12 | 케모센트릭스, 인크. | 보체 성분 C5a 수용체의 비정질 형태 |
| WO2026157730A1 (en) * | 2025-01-21 | 2026-07-30 | Metagone Biotech Inc. | Compositions and methods for treatment of macular degeneration and geographic atrophy |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1739078A1 (de) | 2005-05-30 | 2007-01-03 | Jerini AG | C5a-Rezeptor-Antagonisten |
| CN101611008A (zh) * | 2006-12-22 | 2009-12-23 | 恩希赛弗制药公司 | C3a受体调节剂及其使用方法 |
| CA2714296A1 (en) * | 2008-02-20 | 2009-08-27 | G2 Inflammation Pty Ltd | Humanized anti-c5ar antibodies |
| JP5819730B2 (ja) | 2008-12-22 | 2015-11-24 | ケモセントリックス,インコーポレイティド | C5aRアンタゴニスト |
| US20110275639A1 (en) | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
| DK2585064T3 (en) | 2010-06-24 | 2017-07-24 | Chemocentryx Inc | C5aR antagonists |
| JP6898229B6 (ja) | 2014-09-29 | 2021-07-28 | ケモセントリックス,インコーポレイティド | C5aRアンタゴニスト製造における方法及び中間体 |
| EP3283889B1 (en) | 2015-04-17 | 2020-02-26 | Euroimmun Medizinische Labordiagnostika AG | Method and assay for diagnosing rapidly progressive glomerulonephritis in a subject |
| SG11201808625QA (en) | 2016-04-04 | 2018-10-30 | Chemocentryx Inc | SOLUBLE C5aR ANTAGONISTS |
| KR20200109297A (ko) | 2017-10-31 | 2020-09-22 | 케모센트릭스, 인크. | 소변 sCD163의 C5aR 억제제 감소 |
| JP2021527062A (ja) | 2018-06-07 | 2021-10-11 | ケモセントリックス,インコーポレイティド | ANCA関連血管炎に対するc5aアンタゴニストの投薬及び効果 |
-
2019
- 2019-06-06 JP JP2020567973A patent/JP2021527062A/ja active Pending
- 2019-06-06 IL IL279188A patent/IL279188B2/en unknown
- 2019-06-06 CA CA3102403A patent/CA3102403A1/en active Pending
- 2019-06-06 KR KR1020217000253A patent/KR20210018906A/ko not_active Ceased
- 2019-06-06 MA MA052808A patent/MA52808A/fr unknown
- 2019-06-06 US US16/433,487 patent/US11191756B2/en active Active
- 2019-06-06 SG SG11202011961YA patent/SG11202011961YA/en unknown
- 2019-06-06 WO PCT/US2019/035758 patent/WO2019236820A1/en not_active Ceased
- 2019-06-06 MX MX2020013166A patent/MX2020013166A/es unknown
- 2019-06-06 BR BR112020024842-8A patent/BR112020024842A2/pt unknown
- 2019-06-06 EP EP19814841.3A patent/EP3801519A4/en active Pending
- 2019-06-06 AU AU2019282327A patent/AU2019282327B2/en active Active
- 2019-06-06 KR KR1020267004102A patent/KR20260027358A/ko active Pending
- 2019-06-06 CN CN201980038855.4A patent/CN112423752A/zh active Pending
-
2020
- 2020-12-04 CL CL2020003171A patent/CL2020003171A1/es unknown
- 2020-12-07 ZA ZA2020/07615A patent/ZA202007615B/en unknown
-
2021
- 2021-11-04 US US17/519,266 patent/US12350263B2/en active Active
-
2024
- 2024-05-30 JP JP2024088364A patent/JP2024114706A/ja active Pending